Jaguar Health Inc（JAGX）财务数据JAGXJaguar Health Inc

Jaguar Health Inc (JAGX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Human Health, accounting for 96.1% of total sales, equivalent to $2.86M. Another important revenue stream is Animal Health. Understanding this composition is critical for investors evaluating how JAGX navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Jaguar Health Inc maintains a gross margin of 15.84%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -620.16%, while the net margin is -1045.06%. These profitability ratios, combined with a Return on Equity (ROE) of -865.16%, provide a clear picture of how effectively JAGX converts its operational activities into shareholder value.

In the context of the broader market, JAGX competes directly with industry leaders such as SPRC and ARTL. With a market capitalization of $1.01M, it holds a significant position in the sector. When comparing efficiency, JAGX's gross margin of 15.84% stands against SPRC's N/A and ARTL's N/A. Such benchmarking helps identify whether Jaguar Health Inc is trading at a premium or discount relative to its financial performance.

Jaguar Health's financial performance shows a troubling trend with a net income of -12,701,000 USD in Q2 2026 and a gross margin of only 15.84%, significantly down from previous quarters. The company has also reported a significant decline in revenue, with Q2 2026 revenue at only 1,225,000 USD, a 60% year-over-year decrease.